Keishi Makino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4601224/publications.pdf

Version: 2024-02-01

22	620	623574	752573
papers	citations	14 h-index	20 g-index

23	23	23	1274
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL). Neuro-Oncology Advances, 2020, 2, ii17-ii17.	0.4	0
2	ML-03 RECONSIDERATION OF TREATMENT FOR ELDERLY PATIENTS WITH PRIMARY CENTRAL NERVE SYSTEM LYMPHOMAS. Neuro-Oncology Advances, 2019, 1, ii32-ii32.	0.4	0
3	Differentiating Between Primary Central Nervous System Lymphomas and Glioblastomas: Combined Use of Perfusion-Weighted and Diffusion-Weighted Magnetic Resonance Imaging. World Neurosurgery, 2018, 112, e1-e6.	0.7	18
4	Clinical significance of polyglutamylation in primary central nervous system lymphoma. Acta Neuropathologica Communications, 2018, 6, 15.	2.4	5
5	Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border. EBioMedicine, 2018, 30, 94-104.	2.7	77
6	Additive Value of 3T 3D CISS Imaging to Conventional MRI for Assessing the Abnormal Vessels of Spinal Dural Arteriovenous Fistulae. Magnetic Resonance in Medical Sciences, 2018, 17, 218-222.	1.1	3
7	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathologica Communications, 2018, 6, 134.	2.4	74
8	Machine learning based on multi-parametric magnetic resonance imaging to differentiate glioblastoma multiforme from primary cerebral nervous system lymphoma. European Journal of Radiology, 2018, 108, 147-154.	1.2	41
9	BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma. Journal of Neuro-Oncology, 2018, 140, 115-121.	1.4	16
10	Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma. Oncology Letters, 2017, 14, 264-270.	0.8	3
11	Benefit of 3T Diffusion-weighted Imaging in Comparison to Contrast-enhanced MR Imaging for the Evaluation of Disseminated Lesions in Primary Malignant Brain Tumors. Magnetic Resonance in Medical Sciences, 2017, 16, 217-222.	1.1	2
12	A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact lowâ€grade diffuse astrocytoma. Neuropathology, 2016, 36, 181-186.	0.7	22
13	Quality of Life and Clinical Features of Long-Term Survivors Surgically Treated for Pediatric Craniopharyngioma. World Neurosurgery, 2016, 85, 153-162.	0.7	51
14	Novel metal chelating molecules with anticancer activity. Striking effect of the imidazole substitution of the histidineâ€“pyridineâ€“histidine system. Bioorganic and Medicinal Chemistry, 2015, 23, 5476-5482.	1.4	18
15	Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience. International Journal of Clinical Oncology, 2015, 20, 29-34.	1.0	15
16	Clinical characteristics and pathogenesis of cerebellar glioblastoma. Molecular Medicine Reports, 2014, 10, 2383-2388.	1.1	19
17	Fatty acid synthase is a predictive marker for aggressiveness in meningiomas. Journal of Neuro-Oncology, 2012, 109, 399-404.	1.4	9
18	Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. Journal of Neuro-Oncology, 2012, 106, 155-160.	1.4	37

#	Article	IF	Citations
19	Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study. Annals of Nuclear Medicine, 2011, 25, 432-438.	1.2	76
20	Population-based epidemiological study of primary intracranial tumors in childhood. Child's Nervous System, 2010, 26, 1029-1034.	0.6	74
21	Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature. Brain Tumor Pathology, 2010, 27, 121-125.	1.1	20
22	Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. World Neurosurgery, 2006, 66, 503-506.	1.3	40